Technical Analysis for VRNA - Verona Pharma plc

Grade Last Price % Change Price Change
C 36.93 -5.31% -2.07
VRNA closed down 5.31 percent on Wednesday, November 13, 2024, on 81 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Calm After Storm Range Contraction -5.31%
New 52 Week High Strength -5.31%
Upper Bollinger Band Walk Strength -5.31%
Multiple of Ten Bearish Other -5.31%
Overbought Stochastic Strength -5.31%
Upper Bollinger Band Touch Strength -5.31%
Gapped Down Weakness -5.31%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 7 hours ago
Down 1 ATR about 8 hours ago
Fell Below 10 DMA about 9 hours ago
Down 3% about 9 hours ago
60 Minute Opening Range Breakdown about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company's lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Asthma Respiratory Therapy Chronic Obstructive Pulmonary Disease Respiratory Diseases Cystic Fibrosis Phosphodiesterase Lung Disorders

Is VRNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 40.035
52 Week Low 11.395
Average Volume 1,013,466
200-Day Moving Average 21.42
50-Day Moving Average 32.42
20-Day Moving Average 35.95
10-Day Moving Average 37.56
Average True Range 1.73
RSI (14) 57.81
ADX 42.47
+DI 27.15
-DI 15.99
Chandelier Exit (Long, 3 ATRs) 34.85
Chandelier Exit (Short, 3 ATRs) 36.78
Upper Bollinger Bands 40.08
Lower Bollinger Band 31.81
Percent B (%b) 0.62
BandWidth 23.03
MACD Line 1.83
MACD Signal Line 1.75
MACD Histogram 0.0792
Fundamentals Value
Market Cap 2.95 Billion
Num Shares 79.9 Million
EPS -0.56
Price-to-Earnings (P/E) Ratio -65.95
Price-to-Sales 2981.17
Price-to-Book 5.16
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.90
Resistance 3 (R3) 41.31 40.41 40.24
Resistance 2 (R2) 40.41 39.40 40.20 40.02
Resistance 1 (R1) 38.67 38.77 38.22 38.25 39.80
Pivot Point 37.76 37.76 37.54 37.55 37.76
Support 1 (S1) 36.02 36.75 35.57 35.61 34.06
Support 2 (S2) 35.12 36.13 34.91 33.84
Support 3 (S3) 33.38 35.12 33.62
Support 4 (S4) 32.96